Avoiding Added Matter Pitfalls: Mastering Amendments Before the EPO

​
June 17, 2025

"Added matter" objections are a common and often frustrating hurdle in European patent prosecution. The European Patent Office (EPO) takes a particularly strict stance on claim amendments, especially when compared to more flexible jurisdictions like the United States Patent and Trademark Office (USPTO). To ensure procedural efficiency and help reduce prosecution costs, it is advised that non-European practitioners familiarise themselves with the EPO's approach to added matter.

This article explores the intricacies of added matter objections before the EPO and offers practical advice to help ensure a smoother prosecution process.

What Is Added Matter?

According to Article 123(2) EPC a patent application or granted patent may not be amended in such a way that it contains subject-matter which extends beyond the content of the application as filed. This means that, following an amendment, the skilled person must not be presented with any new technical information that was not already present in the application as filed.

The term "application as filed" refers to the originally filed description, drawings, and claims (but not the abstract). Subject matter from another application that is incorporated by reference is only relevant in very limited circumstances. The "incorporation by reference" doctrine is not generally recognised at the EPO.

The rationale behind this provision is to protect legal certainty. Applicants should not be allowed to improve their legal position by introducing subject matter not originally disclosed, as this could unfairly affect third parties who rely on the original content to assess potential infringement risks.

How Is It Assessed?

The EPO apply the "Gold Standard" test for assessing whether an amendment adds matter (as set out in decisions G 3/89 and G 2/10). The Gold Standard states that an amendment does not add matter beyond the contents of the application as filed if the skilled person, at the filing date, applying their common general knowledge, would directly and unambiguously derive the amendment from the application as filed. This effectively means that if the amended features are not disclosed verbatim in the specification, they must be clearly disclosed in some other manner.

Although added matter is assessed from the viewpoint of the skilled person using common general knowledge, this does not mean that a feature can be added to a claim if the skilled person knows the feature is common in the relevant field. In addition, if a feature is not implicitly or explicitly disclosed, the feature cannot be added to a claim if it is merely rendered obvious by the application's disclosure. In other words, the common general knowledge cannot serve to enlarge or replace, in a subjective or artificial manner, the actual content of the original specification.

Instead, an added feature must be at least implicitly disclosed in the original specification (an implicit disclosure is that which the skilled person would consider is a clear and unambiguous consequence of what is explicitly mentioned in the specification).

How to Avoid Added Matter Objections

General

When filing amended claims, a marked-up version showing the changes should be submitted. In the accompanying submission letter, each amendment must be clearly explained, with precise references to the original application (e.g., specific paragraphs or line numbers). Ideally, relevant excerpts from the description should be quoted directly. It is noted that these rules should be followed whenever amendments are being filed, such as when filing a response to an office action, when filing amended claims for an ex-PCT application, when filing divisional claims, and when filing voluntary claim amendments.

If the amendment is not disclosed verbatim, the submission letter must explain why the skilled person would still directly and unambiguously derive the feature from the original application. Failure to adequately substantiate how the amendments comply with Article 123(2) EPC will usually lead to an objection, and in some cases, the EPO may even decline to conduct a search or continue examination on substantive grounds until a set of claims complying with Article 123(2) EPC is filed.

Intermediate Generalisations

An "unallowable intermediate generalisation" is a particular type of added matter objection where a claim is amended to include a particular feature, but fails to include one or more additional features that are disclosed in combination with that particular feature. As an example, if a claim includes features A and B, and the description describes an embodiment containing features A, B, C and D, it must be assessed whether the claim can be amended to include feature C, but not feature D.

To be allowable, the EPO applies a two-step test (see EPO Guidelines Part H – Chapter V-14, 3.2.1):

  1. The added feature must not be inextricably linked to the omitted features (i.e., the omitted features must not be necessary for achieving the technical effect associated with the added feature); and
  2. The overall disclosure must support the isolation of the added feature and its introduction into the claim.

To avoid an objection based on intermediate generalisation, the submission letter to the EPO should therefore explain why the amendment satisfies this test. Returning to the earlier example, an option would be to point to a part of the description that explains or implies that feature D is optional.

Deletion of Features

An added matter objection can also arise when a feature is removed from an originally filed claim on the ground that a new disclosure of the remaining features in combination without the omitted feature constitutes a new teaching not found in the original specification. To be allowable, the EPO applies a three-step test (as set out in decision T 331/87):

  1. The removed feature must not be described as essential in the original disclosure;
  2. The skilled person must directly and unambiguously recognise that the feature is not indispensable for the function of the invention in the light of the technical problem the invention serves to solve; and
  3. The skilled person must recognise that the removal requires no modification of the other claim features to compensate for the change (it does not in itself alter the invention).

As with intermediate generalisations, the submission letter should clearly demonstrate how these criteria are met.

The "Inescapable Trap"

Under Article 123(3) EPC, a granted European patent cannot be amended in a way that the scope of protection is broadened. In conjunction with an added matter objection, this creates a potential "inescapable trap": if a granted claim is found to contain added matter, but removing the objectionable feature would broaden the claim beyond what was granted, then the patent would be invalid in a manner that could not be cured by amendment (unless there happens to be an alternative amendment that does not involve added matter and is narrower in scope than the amendment held to add matter).

To avoid falling into this trap, it is crucial to assess every amendment for compliance with Article 123(2) before grant. Post-grant, the consequences of added matter are much more severe and may even be fatal to the patent.

The danger of an inescapable trap means that great care must be taken with regard to added matter during prosecution, even if the issue is not raised by the examiner. Moreover, even an amendment suggested by an examiner can be held to involve added matter after grant, so it should not be assumed that an examiner's proposal actually complies with Article 123(2). Responsibility for the amendment always remains with the applicant, even when adopting a course suggested by the examiner.

Final Thoughts

When amending claims in Europe, practitioners must apply a far more rigorous approach than may be required in other jurisdictions, such as the US. Frequently it is found that amendments that are acceptable in the US are objected to in Europe.

In addition to the advice set out above, a patent application can be made more robust at the drafting stage. For example, the following points may be taken into account while drafting a patent application:

  • Optional Features: If a feature is (or could be) optional, say so explicitly or describe alternative embodiments without it. This aids future amendments and helps avoid intermediate generalisation objections;
  • Broad Terminology: Broadening away from specific language used in a specification can be difficult. Accordingly, when describing multiple specific embodiments, include broad language encompassing them. For example, if describing a temperature sensor, pressure sensor, and fluid flow sensor, also state that the device includes "one or more sensors" to preserve flexibility;
  • Finalised Claims: Submit claims that are as complete and final as possible at the outset. If there are several ways to phrase something, include all those options in the description. Avoid relying on prosecution to refine claim language, since post-filing amendments are subject to the EPO's strict added matter provisions.

By understanding and respecting the EPO's stringent approach to added matter, practitioners can better navigate prosecution, reduce costs, and ensure more robust European patents.

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​